Doctors Without Borders condemns Gilead Sciences for refusing to supply its HIV prevention drug, lenacapavir, directly to humanitarian organizations despite months of negotiations. This decision impacts developers and tech professionals working in health tech by highlighting the critical role of corporate ethics in global healthcare access. The situation underscores the need for closer scrutiny of pharmaceutical distribution policies to ensure equitable access to life-saving medications.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



